Predictors of benefits from frontline chemoimmunotherapy in stage IV non-small-cell lung cancer: a meta-analysis

Predictors of benefits from frontline chemoimmunotherapy in stage IV non-small-cell lung cancer: a meta-analysis

Background: Immune checkpoint inhibitors (ICIs) have dramatically expanded the therapeutic landscape of non-small-cell lung cancer (NSCLC). In a previous study, gender, smoking history, and PD-L1 status were found to influence the efficacy of single-agent ICI in NSCLC. This meta-analysis evaluated t...

Full description

Bibliographic Details
Main Authors: Hazem E. El-Osta, Frank E. Mott, Bryan M. Burt, Daniel Y. Wang, Anita L. Sabichi
Format: Article
Language:English
Published: Taylor & Francis Group 2019-12-01
Series:OncoImmunology
Subjects:
atezolizumab
biomarker
immune checkpoint inhibitors
nivolumab
lung cancer and pembrolizumab
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1665974

Internet

http://dx.doi.org/10.1080/2162402X.2019.1665974

Similar Items